Analyst Price Targets — ESTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 31, 2025 9:24 am | Sam Eiber | BTIG | $86.00 | $72.92 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $86 at BTIG |
| December 17, 2025 12:14 pm | — | Canaccord Genuity | $85.00 | $74.15 | TheFly | Establishment Labs price target raised to $85 from $72 at Canaccord |
| December 10, 2025 11:06 am | Mike Matson | Needham | $84.00 | $71.01 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $84 at Needham |
| November 14, 2025 10:39 am | Sam Eiber | BTIG | $81.00 | $64.75 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $81 at BTIG |
| November 6, 2025 11:22 pm | — | Needham | $70.00 | $64.91 | TheFly | Establishment Labs price target raised to $70 from $48 at Needham |
| November 5, 2025 5:20 pm | Sam Eiber | BTIG | $70.00 | $59.55 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $70 at BTIG |
| August 22, 2024 5:50 am | Joanne Wuensch | Citigroup | $45.00 | $44.05 | TheFly | Citi opens 'positive catalyst watch' on Establishment Labs |
| June 6, 2024 6:34 am | Anthony Petrone | Mizuho Securities | $70.00 | $53.89 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $70 at Mizuho |
| April 1, 2024 6:34 am | Anthony Petrone | Mizuho Securities | $65.00 | $50.90 | StreetInsider | Establishment Labs Inc. (ESTA) PT Raised to $65 at Mizuho 'on the potential for US Motiva to receive FDA clearance' |
| December 28, 2022 8:09 am | — | Stephens | $87.00 | $60.45 | Benzinga | Stephens & Co. Maintains Overweight on Establishment Labs Hldgs, Lowers Price Target to $87 |
Latest News for ESTA
Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00. Following the transaction, the director owned 1,182,504 shares of
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and…
Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 3,575 shares of the stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $60.08, for a total value of $214,786.00. Following the completion of the transaction, the director owned 1,220,004
Establishment Labs (NASDAQ: ESTA - Get Free Report) and HealthEquity (NASDAQ: HQY - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Valuation and Earnings This table compares Establishment Labs and
Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ESTA.
U.S. House Trading
No House trades found for ESTA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.